gefitinib has been researched along with thiopental sodium in 20 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (thiopental sodium) | Trials (thiopental sodium) | Recent Studies (post-2010) (thiopental sodium) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 55 | 0 | 52 |
| Protein | Taxonomy | gefitinib (IC50) | thiopental sodium (IC50) |
|---|---|---|---|
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | 0.025 | |
| Tyrosine-protein kinase ABL1 | Mus musculus (house mouse) | 9.69 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.2356 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.044 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.044 | |
| Dipeptidyl peptidase 1 | Homo sapiens (human) | 2.1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.044 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.99 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (85.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ercan, D; Gray, NS; Jänne, PA; Zhou, W | 1 |
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Ding, K; Han, C; Huang, Z; Ji, H; Peng, S; Tian, J; Wan, L; Zhang, L; Zhang, Y; Zheng, C | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Ding, K; Han, C; Huang, Z; Ji, H; Lai, Y; Peng, S; Wan, L; Zhang, Y; Zheng, C | 1 |
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
| Bai, F; Ding, K; Ku, X; Li, H; Liu, X; Tu, Z; Xu, Y; Zhang, L; Zhao, Z; Zhou, W | 1 |
| Ding, K; Han, C; Huang, Z; Ji, H; Lai, Y; Peng, S; Wan, L; Zhang, Y | 1 |
| Becker, C; Engel, J; Eppmann, S; Getlik, M; Grütter, C; Heil, J; Heuckmann, JM; Hoffgaard, F; Kast, SM; Keul, M; Kibies, P; Krüll, J; Lategahn, J; Mayer-Wrangowski, S; Menninger, S; Ortiz-Cuaran, S; Rauh, D; Richters, A; Schaumann, N; Schultz-Fademrecht, C; Sos, ML; Termathe, M; Thomas, RK; Tinnefeld, V; Tomassi, S; Uhlenbrock, N; Zahedi, RP | 1 |
| Gong, P; Jiang, N; Ma, Z; Qin, M; Wang, T; Xie, H; Xu, B; Zhao, Y | 1 |
| Ansari, A; Noolvi, M; Patel, HM; Pawara, R; Surana, S | 1 |
| Döring, E; Engel, J; Günther, M; Juchum, M; Keul, M; Lategahn, J; Laufer, S; Rauh, D; Tumbrink, HL | 1 |
| Baumann, M; Becker, C; Engel, J; Goebel, L; Günther, G; Hengstler, JG; Hennes, E; Keul, M; Lategahn, J; Müller, H; Rauh, D; Schultz-Fademrecht, C; Smith, S; Tumbrink, HL; Unger, A | 1 |
| Chen, ZS; Korlipara, V; Lei, Z; Romu, AA; Zhou, B | 1 |
| Hou, W; Ma, Y; Ren, Y; Sun, H; Yan, B; Zhang, Z | 1 |
| Ding, K; Lu, X; Smaill, JB | 1 |
| Chen, D; Jiang, S; Li, Z; Liao, C; Liu, Y; Ni, Y; Qiang, L; Qiu, Y; Tu, Z; Wang, D; Yao, Y; Zhang, K; Zhang, W | 1 |
| An, B; Chen, C; Fan, R; Li, J; Li, X; Song, X; Wei, S; Zhang, Q; Zou, Y | 1 |
| Butaney, M; Capelletti, M; Ercan, D; Garraway, LA; Goetz, EM; Gray, NS; Ivanova, EV; Jänne, PA; Lazzara, MJ; Letai, A; Maertens, O; Monast, CS; Montero, J; Pratilas, CA; Repellin, C; Rogers, A; Rosen, N; Shimamura, T; Sholl, L; Tadi, M; Wong, KK; Xu, C; Yanagita, M | 1 |
| Hasegawa, T; Hirai, S; Kojima, T; Niki, T; Nishikiori, H; Sakuma, Y; Takahashi, H; Watanabe, A; Yamada, G; Yamaguchi, M | 1 |
1 review(s) available for gefitinib and thiopental sodium
| Article | Year |
|---|---|
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Topics: Chemistry, Pharmaceutical; Humans; Point Mutation; Protein Kinase Inhibitors | 2020 |
19 other study(ies) available for gefitinib and thiopental sodium
| Article | Year |
|---|---|
Discovery of selective irreversible inhibitors for EGFR-T790M.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Mutation; Protein Kinase Inhibitors; Small Molecule Libraries; Structure-Activity Relationship | 2011 |
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Activation; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; NF-kappa B; Nitric Oxide; Oxadiazoles; Pyrimidines; Signal Transduction; Transplantation, Heterologous | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Free Radical Scavengers; Gefitinib; Humans; Nitric Oxide; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction | 2013 |
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Computational Biology; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Models, Chemical; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pteridines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Molecular Structure; Nitric Oxide; Oxadiazoles; Pyrimidines; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2014 |
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane Permeability; Crystallography, X-Ray; Databases, Chemical; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Kinetics; Lung Neoplasms; Models, Molecular; Molecular Conformation; Mutation; Pyrazoles; Pyrimidines; Quinazolines; Small Molecule Libraries; Solubility; src-Family Kinases; Structure-Activity Relationship | 2015 |
Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; HT29 Cells; Humans; Hydrazones; Molecular Structure; Mutant Proteins; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2015 |
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
Topics: A549 Cells; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Lung Neoplasms; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2017 |
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2017 |
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
Topics: Acrylamides; Animals; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mutagenesis, Site-Directed; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2017 |
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Nicotinamide Phosphoribosyltransferase; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2012 |
Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
Topics: Acrylamides; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mutation; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2016 |